📰 Advanced Solid Tumors News
Page 8 - Advanced Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.
April 23, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...
April 15, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
April 11, 2022
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. . Such investors are advised to contact... | April 11, 2022
April 11, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...
February 4, 2022
Investegate announcements from Hutchmed China Ltd, Phase Ib/II Combination Study of HMPL-453
January 14, 2022
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation
December 20, 2021
Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell Non-Hodgkin Lymphomas SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, to...
December 20, 2021
Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell...
December 20, 2021
Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell...
December 13, 2021
“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.